Petyaev Ivan M, Dovgalevsky Pavel Y, Klochkov Victor A, Chalyk Natalya E, Pristensky Dmitry V, Chernyshova Marina P, Udumyan Ruzan, Kocharyan Taron, Kyle Nigel H, Lozbiakova Marina V, Bashmakov Yuriy K
Lycotec Ltd Cambridge UK.
Institute of Cardiology Saratov Russia.
Food Sci Nutr. 2018 Aug 13;6(6):1770-1777. doi: 10.1002/fsn3.734. eCollection 2018 Sep.
Oxidative stress and antioxidant deficiency play a pivotal role in initiation, development, and outcomes of cardiovascular disease. Pharmacokinetic parameters as well as the impact of highly bioavailable lycopene on cardiovascular variables, markers of inflammation and oxidation were investigated during a 30-day clinical trial in patients with coronary vascular disease. The patients were randomized into two major groups and were supplemented with a single 7 mg daily dose of lycopene ingested either in the form of lactolycopene (68 patients) or in the form of lycosome-formulated GA lycopene (74 patients). The endpoints included cardiovascular function parameters, serum lipids, and four markers of oxidative stress and inflammation. Ingestion of lycosome-formulated lycopene increased serum lycopene levels by 2.9- and 4.3-fold, respectively, after 2 and 4 weeks of the trial, whereas supplementation with lactolycopene upregulated serum lycopene by half-fold only after 4 weeks of ingestion. Lycosome formulation of lycopene resulted by the end of the trial in a threefold reduction in IgG and reduction to the same degree of the inflammatory oxidative damage marker. The decrease in oxidized LDL caused by lycosome-formulated lycopene was fivefold. Moreover, supplementation with lycosome-formulated lycopene was accompanied by a significant increase in tissue oxygenation and flow-mediated dilation by the end of the observational period. In contrast, lactolycopene did not cause any significant changes in the parameters studied. Therefore, enhanced bioavailability of lycopene promotes its antioxidant and anti-inflammatory functions and endorses a positive effect of lycopene on cardiovascular system.
氧化应激和抗氧化剂缺乏在心血管疾病的发生、发展及预后中起关键作用。在一项针对冠心病患者的30天临床试验中，研究了高生物利用度番茄红素的药代动力学参数及其对心血管变量、炎症和氧化标志物的影响。患者被随机分为两大组，分别补充每日单剂量7毫克的番茄红素，其中一组以乳糖番茄红素形式摄入（68例患者），另一组以脂质体配方的GA番茄红素形式摄入（74例患者）。终点指标包括心血管功能参数、血脂以及氧化应激和炎症的四项标志物。在试验的第2周和第4周后，摄入脂质体配方番茄红素分别使血清番茄红素水平提高了2.9倍和4.3倍，而补充乳糖番茄红素仅在摄入4周后使血清番茄红素上调了0.5倍。到试验结束时，脂质体配方的番茄红素使IgG降低了三倍，并使炎症氧化损伤标志物降低到相同程度。脂质体配方的番茄红素使氧化型低密度脂蛋白的降低幅度为五倍。此外，在观察期结束时，补充脂质体配方的番茄红素伴随着组织氧合和血流介导的血管舒张显著增加。相比之下，乳糖番茄红素对所研究的参数没有引起任何显著变化。因此，番茄红素生物利用度的提高促进了其抗氧化和抗炎功能，并证实了番茄红素对心血管系统的积极作用。
